

1 **TITLE:**

2 Understanding the Impact of Temperate Bacteriophages on Their Lysogens Through
3 Transcriptomics

4
5 **AUTHORS AND AFFILIATIONS:**

6 Revathy Krishnamurthi¹, Enrique González-Tortuero², Grace Plahe², Ian B. Goodhead², Joanne
7 L. Fothergill¹, Chloë E. James², Heather E. Allison¹

8
9 ¹Department of Clinical Infection, Microbiology and Immunology, Institute of Infection,
10 Veterinary and Ecological Sciences (IVES), University of Liverpool, Liverpool, United Kingdom

11 ²School of Science, Engineering, and Environment, University of Salford, Salford, United
12 Kingdom

13
14 Email address of the co-authors:

15 Revathy Krishnamurthi (Revathy.Krishnamurthi@liverpool.ac.uk)

16 Enrique González-Tortuero (e.gonzalezortuero@salford.ac.uk)

17 Grace Plahe (G.Plahe@edu.salford.ac.uk)

18 Ian B. Goodhead (I.B.Goodhead@salford.ac.uk)

19 Joanne L. Fothergill (jofoth@liverpool.ac.uk)

20 Chloë E. James (c.james@salford.ac.uk)

21
22 Email address of the corresponding author:

23 Heather E. Allison (hallison@liverpool.ac.uk)

24
25 **SUMMARY:**

26 This protocol enables the impact of prophages on their hosts to be revealed. Bacterial cultures
27 are synchronized using conditions that best support the lysogenic state, limiting spontaneous
28 induction. RT-qPCR unequivocally distinguishes prophage-restricted genes and those
29 uncoupled from phage control from those that are expressed during the lytic replication cycle.

30
31 **ABSTRACT:**

32 Temperate phages are found integrated as prophages in the majority of bacterial genomes.
33 Some prophages are cryptic and fixed in the bacterial chromosome, but others are active and
34 can be triggered into a replicative form either spontaneously or by exposure to inducing
35 factors. Prophages are commonly associated with the ability to confer toxin production or
36 other virulence-associated traits on their host cell. More recent studies have shown they can
37 play a much bigger role in altering the physiology of their hosts. The technique described here
38 has enabled us to investigate how prophages affect gene expression in the opportunistic
39 bacterium *Pseudomonas aeruginosa*.

40
41 In this protocol, a portion of bacterial cells within a lysogenic culture is made to undergo lytic
42 replication (spontaneous induction) with a high level of expression per cell of late phage
43 genes, such as those associated with the assembly of phage particles, thus masking the low-
44 level gene expression associated with lysogen-restricted gene expression. In this work, the
45 growth of the wild-type *P. aeruginosa* strain PAO1 was compared with that of isogenic
46 lysogens carrying different combinations of prophages from the Liverpool Epidemic Strain
47 (LES) LESB58.

48

49 Growth profiling experiments were used to identify minimal spontaneous induction during
50 the early exponential growth phase. This study reports how to prepare sample cultures during
51 the early exponential growth phase and how to set up adequate controls despite low cell
52 numbers. These protocols ensure the reliable and reproducible comparison of wild-type and
53 lysogenic bacteria under various conditions, thus improving the transcriptomic profiling of
54 prophage genomes and aiding in the identification of previously unrecognized prophage
55 functions.

56

57 **INTRODUCTION:**

58 Recently, phage therapy for tackling antimicrobial resistance¹ and CRISPR-Cas-based gene
59 editing² have generated renewed interest in bacteriophage research. Again, advancements in
60 biotechnology have enabled the deeper investigation of the interactions between bacteria
61 and phages³. However, the therapeutic use of phage (“phage therapy”) is hampered by
62 concerns about phages acting as mobile genetic elements with the capacity to transfer
63 virulence and resistance genes horizontally⁴. The expanse of “dark matter”⁵ (genes with
64 unknown functions) is both troubling and enticing. Dark matter is considered a gap or a hole
65 in our understanding of phage biology and a largely untapped resource for molecular tools
66 and potential novel therapeutics⁶. The development of high-throughput sequencing
67 techniques, along with improved gene annotation⁷⁻⁹ and new peptide-folding algorithms¹⁰, is
68 improving the detection, description, and functional prediction of phage genomes. However,
69 science is still far from validating phage gene functions in culture or in the real world.

70

71 RNA sequencing (RNA-Seq) can globally map gene expression during phage infection and has
72 significantly improved the understanding of both the phage and bacterial elements involved
73 in lytic and lysogenic cycles^{11,12}. During lysogenic processes, temperate phage genomes are
74 integrated into bacterial DNA to become prophages¹³. Global gene expression profiling
75 experiments can be used to identify prophage-restricted genes that are encoded on
76 temperate phage genomes but only expressed during the lysogenic state¹¹. Such genes do not
77 encode phage structural proteins and are not involved in any phage infection processes. RNA-
78 Seq can be used to identify those genes that are more likely to influence the biology of the
79 bacterial host, either by inducing a gain of function or regulating the existing bacterial genes,
80 thus often enabling the bacteria to adapt to changing environments. Therefore, the ability of
81 prophages to act as microbial puppet masters, controlling a range of bacterial functions, could
82 be studied.

83

84 There are two major barriers to the effective analysis of prophage-restricted gene expression.
85 Firstly, the availability of susceptible hosts is a key issue. By definition, prophages are already
86 incorporated into their specific host genome, so it is challenging to find a susceptible wild-
87 type host to compare the global gene expression in the presence and absence of the
88 prophage. Finding a suitable host to compare the global gene expression, which can be
89 achieved either through the *de novo* infection of another susceptible host or the deletion of
90 the prophage from the original wild-type isolate, without disrupting the rest of the host
91 genome is challenging. The second barrier lies in the heterogeneous nature of lysogenic
92 populations. Some prophages degrade through mutation or recombination to become
93 “cryptic”, meaning they are fixed in a specific location of the bacterial genome. However,
94 other prophages are “active” and can be induced into a replicative, lytic cycle spontaneously

95 or after exposure to inducing factors. In many lysogenic cultures, the rate of spontaneous
96 induction means that a proportion of the bacterial cells are always undergoing lytic phage
97 replication^{14–16}. A high level of expression of late phage genes in these populations masks the
98 low-level gene expression associated with lysogen-restricted gene expression^{11,17}. The
99 proportion of lysogens undergoing spontaneous prophage induction may vary with the
100 growth state, growth conditions, or other triggers. Therefore, to study the impacts of
101 prophages upon the lysogen, spontaneous prophage induction events must be minimized as
102 much as possible by optimizing the growth conditions to favor the lysogenic state.
103

104 This study reports the preparatory work done to investigate the influence of a set of
105 cohabiting prophages from the Liverpool Epidemic Strain (LES) of *Pseudomonas aeruginosa*.
106 Active prophages were isolated from LES and used to infect the model *P. aeruginosa* host
107 strain, PAO1^{16,18,19}. The whole genomes of the wild-type *P. aeruginosa* strain, PAO1, and its
108 lysogen, PAO1Φ2, were sequenced (at a depth of 30x coverage) to ensure the identity of the
109 wild-type strain and to confirm that the lysogen was isogenic. The LES has been associated
110 with increased morbidity and mortality in cystic fibrosis patients, and LES phages¹⁹ have been
111 suggested to aid adaptation to the cystic fibrosis lung environment^{16,19–20}. Despite strong
112 evidence that these prophages affect the biology of their host^{20,21}, the majority of their gene
113 functions are yet to be characterized, and the specific mechanisms of interaction are poorly
114 understood. A transcriptomics approach can empirically uncover the prophage gene
115 functions in a controlled host background. Since spontaneous induction can affect expression
116 profiles, this article describes how to optimize the growth conditions to favor the lysogenic
117 state. Such synchronization of cultures can be validated by real-time PCR to quantify the
118 expression levels of key genetic markers that are associated with crucial stages of LES phage
119 replication in PAO1. The same approach has been used previously to identify the prophage-
120 restricted functions of Shiga-toxicogenic phages that affect motility, acid resistance, and
121 antimicrobial resistance in *Escherichia coli*^{11,17,21,22}.

122 123 **PROTOCOL:**

124 **1. Create a selectable indicator host (Figure 1)**

125
126 NOTE: Phage culture lysates can contain contaminating cells from the original bacterial host.
127 Having an antibiotic-resistant indicator strain allows for the discrimination between the
128 indicator strain and the original bacterial host of the prophage. Using a selectable indicator
129 strain enables the accurate enumeration of the infective phage particles without requiring
130 centrifugation or filtration steps to remove the phage from the lysogen cells following the
131 phage amplification steps. The selectable indicator host strain also reduces the time and
132 number of steps for phage enumeration so that multiple conditions can be trialed
133 simultaneously.
134

135 1.1. Identify a suitable indicator host strain susceptible to lytic and lysogenic infection by
136 the temperate phage of interest. The *P. aeruginosa* lab strain PAO1^{18,20} was used and is
137 susceptible to the three LES phages (LESΦ2, LESΦ3, and LESΦ4).
138

139 1.2. Choose a suitable selective agent (rifampicin was used here), and perform a broth
140 dilution assay to determine the minimum inhibitory concentration (MIC) for the indicator host
141 ($16 \mu\text{g}\cdot\text{mL}^{-1}$ is the MIC for PAO1)^{23,24}.

142

143 1.3. Sequentially expose the indicator host cultures to increasing concentrations of the
144 selective agent in lysogeny broth (LB), starting below the MIC (in this case $5 \mu\text{g} \cdot \text{mL}^{-1}$), for 18–
145 24 h, with shaking, and at $37 \text{ }^\circ\text{C}$.

146

147 1.4. Transfer the culture growing at the highest concentration at a ratio of 1:100 (inoculum
148 to medium) into two-fold increased concentrations of the selective agent (18–24 h each time)
149 until the MIC has been increased sufficiently. PAO1 became a rifampicin-resistant strain
150 (PAO1-Rif^R) at $300 \mu\text{g} \cdot \text{mL}^{-1}$ rifampicin.

151

152 **2. Temporal direct enumeration of spontaneous induction (Figure 2)**

153

154 2.1. Set up overnight starter cultures of both the lysogen (e.g., *P. aeruginosa* PAO1 lysogen
155 harboring LES phages) and indicator host (PAO1-Rif^R) by inoculating a single colony in 5 mL of
156 LB, and incubate at $37 \text{ }^\circ\text{C}$ with shaking at 180 rpm (18–24 h).

157

158 2.2. Set up fresh lysogen and indicator host cultures by inoculating the overnight cultures
159 in 100 mL of LB at a ratio of 1:100, and incubate at $37 \text{ }^\circ\text{C}$ with shaking (180 rpm).

160

161 2.2.1. Monitor the lysogen growth by measuring the OD_{600} and viable count using the Miles
162 Misra technique²⁵. To do this, collect a 1 mL sample from each lysogen culture every hour
163 from the point of inoculation for 8 h.

164

165 2.2.2. Serially dilute the sample immediately after collection by adding 100 μL of the sample
166 into 900 μL of the respective medium. Vortex well at the maximum speed, discard the tip at
167 each dilution, and continue the dilution series from 10^{-1} to 10^{-9} .

168

169 2.2.3. Spot 10 μL of the required dilutions in triplicate onto an LB agar plate, allow to dry,
170 and incubate at $37 \text{ }^\circ\text{C}$ for 18–24 h.

171

172 2.2.4. To calculate the number of viable bacterial cells, find a dilution with easily countable
173 colonies. Count the number of colonies in each spot, and then use the following formula:

174

$$\begin{aligned} \text{CFU} \cdot \text{mL}^{-1} = & \text{mean number of colonies} \times \text{dilution factor} \\ & \times 100 \text{ (mL conversion factor from the dilution series)} \end{aligned}$$

176

177
178 NOTE: As the lysogen culture grows, active phage particles will be produced by spontaneous
179 induction. The production of infective phages means that the transcriptome of the lysogen
180 population is now contaminated with lytic replication cycle-associated gene expression from
181 the lytic phage replication signal and the corresponding host cell response. It is, thus,
182 important to identify the growth stage at which the proportion of lysogenic cells to free
183 infective phage particles is highest in order to limit as much background transcription noise
184 (generated by the lytic phage transcriptome) as possible in the data set.

185

186 2.3. To enumerate the infective phage particles in each temporal sample, inoculate 5 mL
187 of sterile 0.4% bacteriological agar in LB (top agar) with 100 μL of mid-exponential phase
188 indicator host (OD_{600} : 0.4–0.5; in this case, PAO1-Rif^R) in the presence of an appropriate

189 selective agent (50 $\mu\text{g}\cdot\text{mL}^{-1}$ rifampicin in this case, as the MIC of the PAO1 host is only 16
190 $\mu\text{g}\cdot\text{mL}^{-1}$; see **Table of Materials**, row 8 and row 9)

191

192 2.3.1. Spot 10 μL of the same serial dilution (see step 2.2.2) onto the inoculated top agar
193 layer, and allow to dry before incubating at 37 °C for 18–24 h.

194

195 2.3.2. To calculate the infective phage particles, find a dilution with easily countable plaques.
196 Count the number of plaques in each spot.

197

$$198 \quad PFU \cdot \text{mL}^{-1} = \text{mean number of plaques} \times \text{dilution factor} \\ 199 \quad \quad \quad \times 100 \text{ (mL conversion factor from the dilution series)}$$

200

201 2.3.3. Find the time/condition for which the spontaneous induction per CFU (colony forming
202 unit) is minimal for the further experimental steps.

203

204 **3. Preparation of un-induced and induced lysogen cultures for RNA extraction (Figure** 205 **3)**

206

207 3.1. Set up a fresh overnight culture by inoculating a single colony of the lysogen in 5 mL
208 of LB, and incubate at 37 °C with shaking (180 rpm) for 18–24 h.

209

210 3.2. Subculture the overnight culture in 80 mL of LB at a ratio of 1:100 in eight 250 mL
211 flasks.

212

213 3.3. Label the first flask as “un-induced” and the others as “induced”, along with the time
214 points when each sample should be harvested (i.e., “induced t = 0”, “induced t = 10 min”,
215 “induced t = 20 min”, etc.; **Figure 3**).

216

217 3.4. After 90 min of incubation, when the OD_{600} is between 0.1–0.2, or at the time of
218 minimal spontaneous induction (see the discussion), add 4 μL of 1% glacial acetic acid (v/v) to
219 the un-induced flask (**Figure 3**).

220

221 NOTE: As the inducing agent in this work was made using 1% glacial acetic acid as the solvent,
222 the same amount of solvent was added alone as a control step. Alternative controls may be
223 considered depending on the preparation of different inducers.

224

225 3.5. Add the 80 mL culture from the un-induced flask to 720 mL of sterile LB, and
226 immediately add the stop solution (ice-cold 5% [v/v] phenol, pH 4.3, 95 % [v/v] ethanol) using
227 a volume that is 20% of the culture volume (160 mL), and incubate on ice for a minimum of
228 30 min and no longer than 2 h to stabilize the RNA transcripts^{12,26,27}. This is the un-induced
229 sample.

230

231 3.6. Induce the remaining cultures in seven 250 mL flasks (**Figure 3**) with the MIC of an
232 appropriate inducing agent (in this case, 25 $\text{mg}\cdot\text{mL}^{-1}$ norfloxacin, prepared in 1% glacial acetic
233 acid [w/v], used at a final concentration of 1 $\mu\text{g}\cdot\text{mL}^{-1}$), mix well, and incubate at 37 °C and
234 with shaking at 180 rpm for 1 h.

235

236 NOTE: This step will force the lysogen culture into a more coordinated state of lytic
237 replication. Most cells in the culture will begin to undergo lytic production of infective phage
238 particles.

239

240 3.7. Allow the cells to recover by adding 80 mL of culture from the induced flask to 720 mL
241 of sterile LB, which effectively dilutes the inducing agent. Harvest the bacterial cells from each
242 flask every 10 min from time 0 until 1 h by adding a stop solution, as mentioned in step 3.5.

243

244 NOTE: The stop solution stabilizes the RNA for up to 2 h. However, to enhance the sample
245 stability perform all the further steps at 4 °C.

246

247 3.8. Harvest by centrifugation at 10,000 x *g* for 15 min at 4 °C as soon as possible, not
248 exceeding 2 h post-treatment to avoid RNA degradation.

249

250 3.9. Discard the supernatant, and gently resuspend the bacterial pellets in the residual
251 liquid using an adjustable automatic pipette before transferring each sample to a 1.5 mL
252 microfuge tube.

253

254 3.10. Centrifuge the microfuge tubes at high speed (13,000 x *g*) in a microfuge at 4 °C for 1
255 min, and discard the residual supernatant.

256

257 3.11. Flash-freeze the pellets by plunging each sealed microfuge tube into liquid nitrogen.
258 This will aid the efficient lysis of the cells for RNA extraction.

259

260 3.12. Add TRIzol (1 mL) to each frozen pellet, and homogenize the suspension by pipetting
261 (do not vortex). Store at -80 °C until ready to perform RNA extraction for all the samples.

262

263 NOTE: The protocol can be paused at this point.

264

265 3.13. Repeat steps 3.1–3.13 with three biological replicates.

266

267 4. Isolation of RNA from un-induced and induced lysogen cultures

268

269 CRITICAL: All these steps should be performed in an RNase-free environment²⁸. The
270 workbenches should be wiped with 10% NaClO or proprietary RNase inactivators. The
271 labware should be treated with RNase inhibitors such as DEPC treatment, and nuclease-free
272 water should be used in all the reactions.

273

274 4.1. Thaw the frozen TRIzol-treated pellets from step 3.12 on ice, and add 400 µL of
275 molecular biology-grade chloroform.

276

277 4.2. Agitate the vials well by inversion for 10 s to complete the lysis of all cells (do **not**
278 vortex). Then, incubate at room temperature (21 °C) for 2–5 min.

279

280 4.3. Separate the aqueous layer from the TRIzol/chloroform mix by centrifugation using a
281 refrigerated table-top microfuge at 4 °C and 13,000 x *g* for 15 min.

282

283 4.4. Collect the aqueous phase (~ 500 μ L, top layer) using a 1,000 μ L pipette, taking care
284 not to disturb the interphase or organic phase (bottom layer). Transfer to a new 1.5 mL
285 microfuge tube.

286

287 4.5. Add 450 μ L of molecular biology-grade isopropanol to the separated aqueous phase,
288 mix well by inversion (do **not** vortex), and incubate at room temperature (21 $^{\circ}$ C) for 30 min.

289

290 4.6. Recover the RNA by centrifugation using a refrigerated centrifuge at 4 $^{\circ}$ C and 13,000
291 $\times g$ for 30 min.

292

293 4.7. Discard the supernatant without disturbing the RNA pellet, and wash the pellet twice
294 with 800 μ L of 70 % ethanol prepared with nuclease-free water (do not pipette up and down).
295 Ensure the stability of the RNA pellet by repeating the centrifugation step for 5 min after each
296 wash.

297

298 4.8. Discard the ethanol, and air-dry the pellet.

299

300 NOTE: Aspirate the ethanol around the pellet carefully using a 10 μ L microtip, and dry the
301 pellet by inverting the tube on clean blotting paper. The RNA pellet should turn colorless, and
302 the edges should appear ruffled and visible. Drying too little can leave residual ethanol that
303 can impact downstream processes, and drying the pellet too much can make the
304 resuspension difficult.

305

306 4.9. Resuspend the RNA in nuclease-free water (50 μ L) by incubating at 65 $^{\circ}$ C on a thermo-
307 shaker with intermittent mixing (every 30 s) for a total of 3–5 min.

308

309 CRITICAL: The 2'-OH group of RNA is capable of catalyzing the autocleavage of RNA strands
310 at a high temperature above 65 $^{\circ}$ C and a high pH. Temperatures below 65 $^{\circ}$ C will retard the
311 resuspension of the residual DNA, thus limiting the amount of DNA that must be digested at
312 a later stage with DNase I digestion. Hence, keeping the temperature at 65 $^{\circ}$ C is critical to
313 obtain the best samples.

314

315 NOTE: The protocol can be paused at this point, and the samples can be stored at -80° C.

316

317 **5. Removal of contaminating DNA from the RNA by DNase treatment**

318

319 5.1. To remove contaminating DNA from the total RNA before the first-strand cDNA
320 synthesis, add a 0.1 volume of 10x DNase buffer and 1 μ L of DNase enzyme to 10 μ g of total
321 RNA. Mix the tube gently, and incubate at 37 $^{\circ}$ C for 30 min.

322

323 5.2. Resuspend the DNase inactivation reagent, and add a minimum of 2 μ L or a 10%
324 volume of the total reaction volume. Mix well, and incubate the samples for 5 min at room
325 temperature (21 $^{\circ}$ C) during the redispersion of the DNase inactivation reagent.

326

327 5.3. Pellet the DNase reagents by centrifugation using a table-top microcentrifuge at
328 10,000 $\times g$ for 1.5 min.

329

330 5.4. Transfer the supernatant containing the RNA to a fresh tube without disturbing the
331 pellet.

332

333 NOTE: Check the quality of RNA using a 1 μ L scale UV spectrophotometer and microfluidic-
334 based nucleic acid computer analyzer as per the manufacturer's instructions; purified total
335 RNA can be stored at $-80\text{ }^{\circ}\text{C}$. For qRT-PCR, RNA could be used directly at this point. For more
336 sensitive downstream processes, such as RNA sequencing, that require stringent sample
337 quality, an $A_{260/230}$ ratio of ≥ 2.0 must be reached to proceed further.

338

339 5.5. Make up the volume of the DNA-free RNA solution to 500 μ L using nuclease-free
340 water.

341

342 5.6. Add 50 μ L of nuclease-free 3 M sodium acetate (pH 5.3) and 495 μ L of isopropanol.
343 Mix well, and incubate at room temperature for 30 min.

344

345 NOTE: This step will precipitate the RNA.

346

347 5.7. Recover the RNA by centrifugation at 13,000 $\times g$ and $4\text{ }^{\circ}\text{C}$ for 30 min.

348

349 5.8. Wash the RNA pellet thrice with ice-cold 70% ethanol by centrifuging the samples at
350 13,000 $\times g$ and $4\text{ }^{\circ}\text{C}$ for 5 min after each wash to remove the salts completely.

351

352 5.9. Check the quality of the RNA using a 1 μ L scale UV spectrophotometer and
353 microfluidic-based nucleic acid computer analyzer as per the manufacturer's instructions;
354 purified total RNA can be stored at $-80\text{ }^{\circ}\text{C}$.

355

356 NOTE: The guide²⁹ was used to achieve the RNA quality standards. If the $A_{260/230}$ ratio is <2.0 ,
357 then repeat steps 5.5–5.9.

358

359 **6. Qualitative and quantitative analysis of the DNase-free RNA**

360

361 6.1. Validate the efficiency of the DNase treatment for each sample by performing a
362 quantitative PCR using 16S rRNA primers (**Table 2**) with 1 μ g of total RNA, and confirm that
363 no amplification product is produced.

364

365 NOTE: The ideal primers to assess gDNA contamination would be primers that are designed
366 to anneal at intron-exon junctions or regulatory regions in prokaryotes or at transcriptionally
367 inactive sites^{30,31}.

368

369 6.2. Determine the RNA integrity number (RIN) using a microfluidic-based nucleic acid
370 computer analyzer as per the manufacturer's instructions.

371

372 NOTE: Samples that show an $\text{RIN} \geq 9$ should be used for the first-strand synthesis. Samples
373 that show an $\text{RIN} < 9$ should be discarded, and the isolation steps (1.1–5.4) should be
374 repeated.

375

376 6.3. Quantify the total RNA concentration using the HS RNA assay kit and a fluorimeter
377 according to the manufacturer's instructions.

378

379 **7. First-strand cDNA synthesis**

380

381 7.1. Prepare an RNA primer mixture for each sample by mixing 1 μL of total RNA with 1 μL
382 of random hexamers (50 $\text{ng}\cdot\mu\text{L}^{-1}$) and 1 μL of 10 mM dNTP mix. Then, adjust the total volume
383 to 10 μL using nuclease-free water.

384

385 7.2. Incubate the reaction at 65 $^{\circ}\text{C}$ for 5 min, and place on ice for 1 min.

386

387 7.3. Prepare a cDNA synthesis mix for each sample by adding 2 μL of 10x RT buffer; 4 μL of
388 25 mM MgCl_2 ; 2 μL of 0.1 M DTT; 1 μL of RNase inhibitor (40 $\text{U}\cdot\mu\text{L}^{-1}$); and 1 μL of the reverse
389 transcription reagent (200 $\text{U}\cdot\mu\text{L}^{-1}$) in the indicated order.

390

391 7.4. Add the cDNA synthesis mix to the RNA/primer mixture. Mix gently, and centrifuge
392 the samples briefly to collect the components at the bottom of the tube.

393

394 7.5. Prime the mix by incubating the samples for 10 min at 25 $^{\circ}\text{C}$, followed by 50 min at 50
395 $^{\circ}\text{C}$. Terminate the reactions by incubating at 85 $^{\circ}\text{C}$ for 5 min, and chill on ice.

396

397 7.6. Add 1 μL of RNase H to each tube, and incubate at 37 $^{\circ}\text{C}$ for 20 min to remove the RNA
398 from the DNA:RNA hybrid.

399

400 7.7. Finally, dilute the cDNA synthesis reaction to a total volume of 80 μL , and store it at
401 -80°C until further use.

402

403 NOTE: The protocol can be paused at this point.

404

405 **8. Standard curve and quantitative (q)-PCR to determine the expression levels of** 406 **marker genes that indicate different stages of phage replication**

407

408 8.1. Identify a set of target genes that can act as markers for each stage of replication of
409 the phage of interest. In our case, these were as detailed in **Table 2**.

410

411 8.2. Amplify each of the target genes from the template genomic DNA using relevant
412 primers and using PCR with the following amplification conditions: initial denaturation at 95
413 $^{\circ}\text{C}$ for 2 min; denaturation at 95 $^{\circ}\text{C}$ for 30 s; annealing at the optimal annealing temperature
414 depending on the primers (58 $^{\circ}\text{C}$ was used here) for 30 s; extension at 72 $^{\circ}\text{C}$ for 1 min; and
415 final extension at 72 $^{\circ}\text{C}$ for 5 min.

416

417 8.3. Purify each amplicon using a PCR purification kit, and clone them in a TA cloning
418 vector as per the manufacturer's instructions. Verify the sequence of each cloned product by
419 Sanger sequencing.

420

421 NOTE: The protocol can be paused at this point.

422

423 8.4. Calculate the copy number for individual plasmids using the following equation²⁰:

$$424 \quad \text{Copy number} = \left(\frac{\text{Amount of DNA (ng)} \times 6.022 \times 10^{23} \left(\frac{\text{molecules}}{\text{mol}} \right)}{\text{Length of DNA (bp)} \times \frac{660 \left(\frac{\text{g}}{\text{mol}} \right)}{\text{bp}} \times 10^9 \left(\frac{\text{ng}}{\text{g}} \right)} \right)$$

425

426 8.5. Prepare a standard template for each marker gene by serially diluting the plasmid DNA
427 from 10^9 copies/ μL to 10^2 copies/ μL in molecular-grade nuclease-free sterile H_2O .

428

429 8.6. Perform quantitative PCR according to the manufacturer's instructions for the
430 preferred qPCR system with $1 \mu\text{L}$ of cDNA (from step 7.7) for each sample in triplicate, along
431 with the respective plasmid standards in triplicate; perform the PCR in a 96-well plate for each
432 target.

433

434 8.7. Plot the Log DNA copy number (x-axis) versus the cycle threshold (y-axis, Ct), and use
435 an appropriate platform such as Excel or R to perform a linear regression calculation to display
436 the coefficient of determination (R^2) and a linear equation.

437

438 NOTE: The coefficient of determination should be above 0.98.

439

440 8.8. Estimate the copy number for each target using the linear equation ($y = mx + b$)
441 derived from the linear regression (step 8.7), where y is the estimated Ct; x is the log DNA
442 copy number; m is the slope of the line, which defines the change in the Ct with respect to
443 the DNA copy number; and b is the y-axis intercept that represents the estimated Ct for one
444 DNA copy³².

445

446 8.9. For each marker gene calculate the efficiency of the PCR amplification (E) by using the
447 parameters from the linear regression of the standard curve and the following equation,
448 where m is the slope derived from step 8.7 and step 8.8:

449

$$450 \quad E = 10^{\left(-\frac{1}{m}\right)}$$

451

452 8.10. Validate all the primers in terms of their percent efficiency using the following
453 equation:

454

$$455 \quad \text{Percent Efficiency} = (E - 1) \times 100$$

456

457 NOTE: The efficiency must be in the range of 90%–110%.

458

459 8.11. Calculate the absolute copy number of the DNA using the following formula:

460

$$461 \quad \text{Absolute copy number} = E^{b-Ct}$$

462

463 where Ct (step 8.8) is the cycle threshold, b is the intercept (step 8.8), m is the slope (step
464 8.8), and E is the efficiency of PCR amplification (step 8.9).

465

466 CRITICAL: When comparing the amplification of two or more targets by q-PCR, the PCR
467 efficiency must be calculated for each target in order to compare the absolute DNA copy
468 numbers.

469

470 8.12. In this study, the *16S* rRNA, *proC*, and *rpoD* genes were used as the general internal
471 controls, and *gyrB* was used as an induction control^{33–35}.

472

473 NOTE: When choosing internal controls from the RNA seq data, it is best to select internal
474 controls that do not change in expression levels for the conditions tested. Careful
475 consideration of appropriate controls is always important for the meaningful interpretation
476 of the results.

477

478 **REPRESENTATIVE RESULTS:**

479 In this work, the direct temporal enumeration of the phage production from a PAO1 LESΦ2
480 lysogen culture grown under non-inducing conditions was used to determine the impact of
481 spontaneous LESΦ2 induction under the culturing conditions defined here. The phage density
482 was at its lowest point with a mean of $\sim 2.61 \times 10^6$ plaque forming units (PFU)·mL⁻¹ 2 h after
483 subculture in fresh medium during the early exponential phase of growth, suggesting that
484 lysogeny was the dominant state. The LESΦ2 titer rapidly increased to a mean of $\sim 2.4 \times 10^8$
485 PFU·mL⁻¹ within 4 h and reached the highest density after 6 h (mean of $\sim 5.83 \times 10^9$ PFU·mL⁻¹;
486 **Figure 4**).

487

488 Minimal spontaneous induction was observed during the early log phase of lysogen growth
489 (after 2 h). However, the measurable presence of phages in the culture medium was the result
490 of many prior events, including the following: the packaging of nucleic acids into protein
491 heads, the assembly of proteins into phage particles, and the expression of late phage genes,
492 middle-stage phage genes, and early regulatory phage genes. It was important to catch the
493 infected cells prior to the expression of the phage-associated replication events; hence, 90
494 min was chosen to let the culture grow prior to induction. To capture the gene expression
495 profile of the PAO1, LESΦ2 lysogen samples from a culture were harvested pre-induction and
496 post-induction over a 90 min period, as mentioned in step 3.4. This 90 min time point is well
497 before high levels of spontaneous induction of the resident prophage are detected by the
498 plaque assay from step 2.3.2. Since the bacterial cell density was low during early exponential
499 growth, the culture volumes were scaled up to 800 mL to ensure ample material for the gene
500 expression studies. The samples were collected from the uninduced culture and induced
501 cultures every 10 min, and RNA was extracted to map the expression profile of the key
502 markers for lysogeny and lytic replication during the bacterial growth. Total RNA was purified
503 and validated for the absence of genomic DNA using qPCR assays targeting the *16S* rRNA gene
504 (step 6.1). The samples reaching an RIN ≥ 9 passed quality control and were converted to
505 cDNA.

506

507 The annotated LESΦ2 genome was examined to identify genes that are well-known players
508 in the lysogenic and lytic replication cycles of temperate phages. These identified genes were
509 then used to validate the qRT-PCR for the expression profiling of the lysogen cycle-restricted
510 and lytic cycle-associated genes from induced and un-induced cultures. We quantified the
511 absolute DNA copy number and conducted a Wilcoxon signed-rank test using R³⁶ to compare
512 the expression levels in un-induced and induced cultures (**Figure 5**). A marked increase in the

513 expression of the *cro* gene (an early marker of lytic replication) from $\sim 2.31 \times 10^9$ copies in un-
514 induced cultures to $\sim 3.02 \times 10^{11}$ copies 30 min post-induction (Wilcoxon signed-rank test: $p < 0.01$)
515 was observed. Similarly, O proteins and P proteins, which are mid-stage markers of lytic
516 replication (and are predicted to be involved in phage genome replication), also showed
517 significant upregulation from $\sim 1.74 \times 10^8$ to $\sim 1.25 \times 10^{10}$ copies (Wilcoxon signed-rank test: p
518 < 0.01) and from $\sim 6.05 \times 10^2$ to $\sim 5.68 \times 10^5$ copies (Wilcoxon signed-rank test: $p < 0.01$),
519 respectively. Finally, the tail-associated structural genes were used as late markers of the lytic
520 replication cycle. Again, we observed a significant increase in expression from $\sim 2.31 \times 10^6$
521 copies in un-induced cultures to $\sim 4.38 \times 10^8$ copies 30 min post-induction (Wilcoxon signed-
522 rank test: $p < 0.01$). Thus, the quantitative RT-PCR data confirmed that the gene expression
523 of well-established marker genes for lytic replication followed the expected trend, with the
524 early, mid, and late markers showing multiple-fold differential expression in the predicted
525 order (**Figure 5**). Since the expression of the markers for lytic replication was upregulated 30
526 min post-recovery, this is considered as an appropriate representative time point for studying
527 the transcriptomic landscape of active temperate phages and their bacterial hosts during the
528 lytic cycle.

529
530 We observed some expression of lytic genes in un-induced conditions, confirming that some
531 spontaneous induction always occurs, even in optimized cultures in which the lysogen
532 numbers are represented with the highest ratio of CFU to released PFU in the early log phase.
533 This means that there will always be some level of “noise” in the transcriptomics data, which
534 reinforces the importance of carefully prepared controls, including induced and un-induced
535 cultures. The appropriate choice of the internal control genes to determine the fold changes
536 in expression relies on carefully examining the transcriptomics data to identify genes that are
537 expressed at the same level in both the un-induced and induced samples. Our preliminary
538 results suggest that *rpoD* was the most reliable control gene tested and had the most stable
539 expression ($\sim 1.71 \times 10^5$ copies before induction and $\sim 3.33 \times 10^5$ copies 30 min post-induction;
540 Wilcoxon signed-rank test: $p = 0.3594$) compared to the *16S* rRNA or *proC* genes (**Figure 5**).
541 The variability of the expression of the internal controls led to the measurement of the
542 absolute numbers of transcripts. Future examination of the transcriptomics data will support
543 the choice of appropriate internal controls for further validation.

544
545 The *cI* gene was used in our gene profiling exercise, as it is a well-recognized marker of
546 lysogeny. Compared to the markers for lytic replication, the expression of the *cI* gene was
547 relatively stable (**Figure 5**), but the copy number of this gene was reassuringly high in the un-
548 induced cultures compared to those of the markers for lytic replication. These data are in
549 agreement with the low PFU numbers in the same samples, thus confirming that high
550 repressor expression was associated with lower levels of phage production. The data reported
551 here demonstrate that the expression of the *cI* transcript for this particular phage is not
552 significantly downregulated post-induction, as seen in the Stx phages^{11,17}. Repressor activity
553 is normally controlled at both the transcriptional and post-translational levels, so the
554 repressor gene can be transcribed, but the resultant protein is immediately subjected to
555 autocleavage. Further experimentation is required to validate transcriptional and post-
556 translational controls. Moreover, from our standard curve, the minimum detection limit of
557 qPCR appears to be $\sim 10^2$ copies.

558

559 Together, our findings from plaque and qRT-PCR assays validate our strategy for culture and
560 RNA sample preparation to generate a well-controlled input for RNA-Seq experiments. The
561 un-induced cultures in the early-exponential phase exhibited low levels of spontaneous
562 induction and lytic gene expression, suggesting the dominance of lysogeny. In contrast, the
563 cultures isolated 30 min after induction showed significant increases in the expression of
564 marker genes that indicate the dominance of lytic replication.

565
566 **FIGURE AND TABLE LEGENDS:**

567 **Figure 1: The protocol for creating the rifampicin-resistant indicator host.**

568

569 **Figure 2: The experimental design for enumerating the PFU and CFU of a lysogen from the**
570 **same sample.**

571

572 **Figure 3: The experimental design for sampling induced and un-induced cultures for RNA**
573 **isolation.**

574

575 **Figure 4: Temporal enumeration of spontaneous induction.** Temporal enumeration of
576 spontaneous LES prophage production using the PFU from the PAO1 Φ 2 lysogen with the
577 concurrent CFU, $n = 8$ (two biological and four technical replicates); the error bars represent
578 the standard deviation. The dark red points indicate the $\text{CFU} \cdot \text{mL}^{-1}$ in LB; the dark blue points
579 indicate the $\text{PFU} \cdot \text{mL}^{-1}$ in LB. The spontaneous release of the ϕ 2 infective phage by the
580 lysogens is at the lowest measurable level at 2 h post-inoculation.

581

582 **Figure 5: Absolute copy number of the target marker genes.** The absolute copy number of
583 phage marker genes confirm the predicted expression patterns, derived using RT-qPCR, of
584 genes expected to play important roles in lysogeny and lytic cycles. The dots represent both
585 three biological and three technical replicates ($n = 9$). (A) The red box represents the lysogeny
586 marker, *cl*; (B) green represents the early lytic marker, *cro*; (C,D) blue represents the mid lytic
587 markers, DNA replication genes; (E) magenta represents the late lytic marker, tail structural
588 genes; (F–H) gray represents the host markers that were used as internal controls, and (I)
589 white represents the DNA gyrase B, which was used as an induction control. The solid
590 horizontal lines show the median of the distribution.

591

592 **Table 1: Primers designed in this study.** The sequences of specific primers for the marker
593 genes and internal controls used in this study are provided, along with their corresponding
594 NCBI accession IDs.

595

596 **Table 2: Efficiency of the primers used in this study calculated using the qPCR standard**
597 **curve.**

598

599 **DISCUSSION:**

600 The creation of a selectable indicator host, previously used in plaque assays to more
601 accurately quantify the spontaneous induction of Stx phage from *E. coli* MC1061^{37–39}, has
602 been described here. This intervention has the added benefit of reducing the sample
603 processing steps and time, thus enabling the simultaneous assessment of spontaneous
604 induction rates in multiple culture conditions. There is a risk of generating other mutations
605 during the creation of rifampicin-resistant variants⁴⁰; however, in this work, the evolved strain

606 was only used as an indicator host for the enumeration of plaques from cultures of interest
607 and was not included in the transcriptomic analysis. As long as the selectable indicator strain
608 remains equally susceptible to infection by the phage of interest, there is no concern about
609 other acquired mutations. Nevertheless, no differences in the restriction fragment length
610 polymorphism profiles were detected by the pulse field gel electrophoresis (PFGE) analysis of
611 PAO1^{WT} and PAO1^{RIF} (data not shown).

612
613 When choosing host cells, it is rare to find an indicator strain that does not already harbor
614 prophages. As a case in point, PAO1 harbors the filamentous prophage Pf4. The experimental
615 controls for this study were designed to be able to directly examine the gene expression of
616 specific phages (in this case, LES prophage 2) and the effects this phage has on bacterial gene
617 expression. In the comparison of transcripts from PAO1 carrying the LES prophage 2 and
618 lacking the LES prophage 2 (both lysogen and non-lysogen carry the endogenous Pf4), which
619 serve as internal controls to exclude the impact of Pf4 on the host. Additionally, it has been
620 demonstrated that Pf4 usually does not cause lysis in its host cell⁴¹ and is, therefore, not
621 capable of confounding the results of these experiments.

622
623 It is well-established that careful quality control is crucial in sample preparation for producing
624 meaningful omics data⁴². However, as previously described¹¹, the careful characterization of
625 prophage activity in the preparation of lysogen cultures for such studies is rarely performed.
626 Here, we detail our systematic protocols for producing a well-controlled and optimized
627 culture preparation for transcriptomic studies to better explore the interactions between
628 bacteria and temperate phages. The synchronicity of the population was controlled by
629 bringing the culture through at least four doublings before treating it with the antibiotic
630 norfloxacin. By determining the MIC of the drug norfloxacin for the strain in the study, we
631 could ensure that the concentration of the inducing agent was just above the MIC for the
632 “induction” treatment. The drug-treated cells were then diluted 1:10 to lower the norfloxacin
633 concentration below the MIC after the 1 h treatment in order to allow the cells to recover
634 and complete the phage replication process, ending in the lysis of the cell and the release of
635 infective phage progeny. The cells only enter the lytic replication cycle following the induction
636 stimulus once the concentration of norfloxacin has been brought below the MIC during the
637 recovery period. In this case, going above 1 $\mu\text{g}\cdot\text{mL}^{-1}$ norfloxacin means that the drug could
638 not be effectively diluted below the MIC, as the MIC for norfloxacin for PAO1 is 0.19 $\mu\text{g}\cdot\text{mL}^{-1}$.
639 The level of inducer dilution must be balanced with the need for lysogen recovery and the
640 retention of the culture density for harvesting the RNA. The data discussed here demonstrate
641 that it is possible to synchronize cultures to create samples in which lysogeny dominates, thus
642 reducing the noise from spontaneous induction and enabling the detection of true lysogeny-
643 driven changes in gene expression. Since the lysogenic state is predominant in the early-
644 exponential phase of growth when the bacterial cell density is low, we suggest scaling up the
645 cultures to harvest enough RNA for subsequent gene expression studies such as RNA-Seq.

646
647 The use of norfloxacin as an inducing agent to force cultures into the lytic cycle is well-
648 reported^{43,44}; however, this will also affect the expression of other bacterial genes in the
649 process^{45,46}. To mitigate this, RNA libraries from control wild-type cultures grown under the
650 same inducing and non-inducing conditions should be included in RNA-Seq experiments. The
651 use of internal controls and key marker genes to validate the stages of phage replication by
652 qRT-PCR is also crucial for accurate comparisons. Quantitative RT-PCR profiling cannot be

653 interpreted by comparing the absolute numbers of transcripts for each gene at various time
654 points; it is the shape of the profile that matters. First, only one small region in the transcript
655 for any gene has been sampled, so whether it is a short-lived or longer-lived element is
656 unknown²⁷. Certainly, RNA-Seq mapping of transcripts shows that the density of the mapping
657 data varies significantly over the length of a gene. Secondly, it is the shape of the gene
658 expression profile that should be interpreted for a marker gene associated with the lytic cycle
659 or the lysogenic lifestyle or even uncoupled from the phage regulatory circuits¹¹. Spontaneous
660 induction is a real issue in lysogen culture and will always result in the expression of lytic cycle-
661 associated genes. However, profiling does show that the genes associated with the lytic
662 replication cycle are suppressed in their expression pre-induction (at least two log folds) and
663 up-regulated post-induction.

664
665 The previously conducted transcriptomic analyses of Stx phage interactions with *E. coli*
666 support a thorough understanding of the phage genes involved in maintaining lysogeny and
667 triggering the lytic cycle^{11,17}. Currently, the LES phages of *P. aeruginosa* have been annotated,
668 but their key gene functions are less well understood. Transcriptomic studies will enable the
669 re-annotation of the LES prophages and improve our understanding of the genes involved in
670 the lysogeny and lytic cycle. Linking gene sequence to function represents a major challenge
671 in the study of novel prophages, which further highlights the need for more studies to confirm
672 the phage gene functions for the production of better annotation tools⁴⁷. The wider
673 application and adaptation of the protocols and extra quality control measures detailed in
674 this video article could help in unveiling various prophage functions and, thus, improving
675 annotation pipelines and transforming our understanding of phage and bacterial biology.

676

677 REFERENCES:

- 678 1. Lin, D. M., Koskella, B., Lin, H. C. Phage therapy: An alternative to antibiotics in the age of
679 multi-drug resistance. *World Journal of Gastrointestinal Pharmacology and Therapeutics*. **8**
680 (3), 162–173 (2017).
- 681 2. Jiang, W., Marraffini, L. A. CRISPR-Cas: New tools for genetic manipulations from bacterial
682 immunity systems. *Annual Review of Microbiology*. **69** (1), 209–228 (2015).
- 683 3. Santos, S. B., Azeredo, J. Bacteriophage-based biotechnological applications. *Viruses*. **11**
684 (8), 737 (2019).
- 685 4. Rodríguez-Rubio, L., Jofre, J., Muniesa, M. Is genetic mobilization considered when using
686 bacteriophages in antimicrobial therapy? *Antibiotics*. **6** (4), 32 (2017).
- 687 5. Hatfull, G. F. Dark Matter of the biosphere: The amazing world of bacteriophage diversity.
688 *Journal of Virology*. **89** (16), 8107–8110 (2015).
- 689 6. Yukgehnaish, K. et al. PhageLeads: Rapid assessment of phage therapeutic suitability using
690 an ensemble Machine Learning approach. *Viruses*. **14** (2), 342 (2022).
- 691 7. Seemann, T. Prokka: Rapid prokaryotic genome annotation. *Bioinformatics*. **30** (14), 2068–
692 2069 (2014).
- 693 8. Arndt, D. et al. PHASTER: A better, faster version of the PHAST phage search tool. *Nucleic*
694 *Acids Research*. **44** (W1), W16–W21 (2016
695).
- 696 9. Banerjee, S. et al. FINDER: An automated software package to annotate eukaryotic genes
697 from RNA-Seq data and associated protein sequences. *BMC Bioinformatics*. **22** (1), 205 (2021).
- 698 10. Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. *Nature*.
699 **596** (7873), 583–589 (2021).

- 700 11. Veses-Garcia, M. et al. Transcriptomic analysis of Shiga-toxigenic bacteriophage
701 carriage reveals a profound regulatory effect on acid resistance in *Escherichia coli*. *Applied*
702 *and Environmental Microbiology*. **81** (23), 8118–8125 (2015).
- 703 12. Owen, S. V. et al. A window into lysogeny: revealing temperate phage biology with
704 transcriptomics. *Microbial Genomics*. **6** (2), e000330 (2020).
- 705 13. Davies, E. V., Winstanley, C., Fothergill, J. L., James, C. E. The role of temperate
706 bacteriophages in bacterial infection. *FEMS Microbiology Letters*. **363** (5), fnw015 (2016).
- 707 14. Livny, J., Friedman, D. I. Characterizing spontaneous induction of Stx encoding phages
708 using a selectable reporter system. *Molecular Microbiology*. **51** (6), 1691–1704 (2004).
- 709 15. Fogg, P. C. M. et al. Identification of multiple integration sites for Stx-phage Φ 24B in
710 the *Escherichia coli* genome, description of a novel integrase and evidence for a functional
711 anti-repressor. *Microbiology*. **153** (12), 4098–4110 (2007).
- 712 16. James, C. E. et al. Differential infection properties of three inducible prophages from
713 an epidemic strain of *Pseudomonas aeruginosa*. *BMC Microbiology*. **12**, 216 (2012).
- 714 17. Riley, L. M. et al. Identification of genes expressed in cultures of *E. coli* lysogens
715 carrying the Shiga toxin-encoding prophage Φ 24B. *BMC Microbiology*. **12** (1), 42 (2012).
- 716 18. Stover, C. K. et al. Complete genome sequence of *Pseudomonas aeruginosa* PAO1, an
717 opportunistic pathogen. *Nature*. **406** (6799), 959–964 (2000).
- 718 19. Winstanley, C. et al. Newly introduced genomic prophage islands are critical
719 determinants of in vivo competitiveness in the Liverpool Epidemic Strain of *Pseudomonas*
720 *aeruginosa*. *Genome Research*. **19** (1), 12–23 (2009).
- 721 20. Davies, E. V. et al. Temperate phages enhance pathogen fitness in chronic lung
722 infection. *The ISME Journal*. **10** (10), 2553–2555 (2016)
- 723 21. Allison, H. E. Stx-phages: drivers and mediators of the evolution of STEC and STEC-like
724 pathogens. *Future Microbiology*. **2** (2), 165–174 (2007).
- 725 22. Allison, H. E. et al. Immunity profiles of wild-type and recombinant Shiga-like toxin-
726 encoding bacteriophages and characterization of novel double lysogens. *Infection and*
727 *Immunity*. **71** (6), 3409–3418 (2003).
- 728 23. Mori, N. et al. A peptide based on homologous sequences of the β -barrel assembly
729 machinery component BamD potentiates antibiotic susceptibility of *Pseudomonas*
730 *aeruginosa*. *Journal of Antimicrobial Chemotherapy*. **67** (9), 2173–2181 (2012).
- 731 24. Chojnacki, M. et al. A novel, broad-spectrum antimicrobial combination for the
732 treatment of *Pseudomonas aeruginosa* corneal infections. *Antimicrobial Agents and*
733 *Chemotherapy*. **63** (10), e00777-19 (2019).
- 734 25. Miles, A. A., Misra, S. S., Irwin, J. O. The estimation of the bactericidal power of the
735 blood. *Epidemiology & Infection*. **38** (6), 732–749 (1938).
- 736 26. Srikumar, S. et al. RNA-seq brings new insights to the intra-macrophage transcriptome
737 of *Salmonella Typhimurium*. *PLoS Pathogens*. **11** (11), e1005262 (2015).
- 738 27. Kröger, C. et al. The transcriptional landscape and small RNAs of *Salmonella enterica*
739 serovar Typhimurium. *Proceedings of the National Academy of Sciences of the United States*
740 *of America*. **109** (20), E1277–E1286 (2012).
- 741 28. Green, M. R., Sambrook, J. How to win the battle with RNase. *Cold Spring Harbor*
742 *Protocols*. **2019** (2), pdb.top101857 (2019).
- 743 29. Koetsier, G. A practical guide to analyzing nucleic acid concentration and purity with
744 microvolume spectrophotometers. *New England BioLabs Inc.* At <[https://www.neb.com/-](https://www.neb.com/-/media/nebus/files/application-)
745

746 notes/technote_mvs_analysis_of_nucleic_acid_concentration_and_purity.pdf?rev=c24cea0
747 43416420d84fb6bf7b554dbbb> (2019).

748 30. Saunders, N. A., Lee, M. A. *Real-Time PCR: Advanced Technologies and Applications*.
749 Caister Academic Press. Norfolk, UK (2013).

750 31. Bustin, S. A. *A-Z of Quantitative PCR*. International University Line. La Jolla, CA (2004).

751 32. Ruijter, J. M. et al. Efficiency correction is required for accurate quantitative PCR
752 analysis and reporting. *Clinical Chemistry*. **67** (6), 829–842 (2021).

753 33. Fothergill, J. L., Neill, D. R., Loman, N., Winstanley, C., Kadioglu, A. *Pseudomonas*
754 *aeruginosa* adaptation in the nasopharyngeal reservoir leads to migration and persistence in
755 the lungs. *Nature Communications*. **5** (1), 4780 (2014).

756 34. Huang, J. et al. Temperature-dependent expression of phzM and its regulatory genes
757 lasI and ptsP in rhizosphere isolate *Pseudomonas* sp. strain M18. *Applied and Environmental*
758 *Microbiology*. **75** (20), 6568–6580 (2009).

759 35. Savli, H. et al. Expression stability of six housekeeping genes: a proposal for resistance
760 gene quantification studies of *Pseudomonas aeruginosa* by real-time quantitative RT-PCR.
761 *Journal of Medical Microbiology*. **52** (5), 403–408 (2003).

762 36. Kassambara, A. rstatix: Pipe-Friendly Framework for Basic Statistical Tests. At
763 <<https://CRAN.R-project.org/package=rstatix>> (2022).

764 37. McDonald, J. E. et al. High-throughput method for rapid induction of prophages from
765 lysogens and its application in the study of Shiga toxin-encoding *Escherichia coli* strains.
766 *Applied and Environmental Microbiology*. **76** (7), 2360–2365 (2010).

767 38. Smith, D. L. et al. Short-tailed Stx phages exploit the conserved YaeT protein to
768 disseminate Shiga toxin genes among *Enterobacteria*. *Journal of Bacteriology*. **189** (20), 7223–
769 7233 (2007).

770 39. James, C. E. et al. Lytic and lysogenic infection of diverse *Escherichia coli* and *Shigella*
771 strains with a verocytotoxigenic bacteriophage. *Applied and Environmental Microbiology*. **67**
772 (9), 4335–4337 (2001).

773 40. Rees, V. E. et al. Characterization of hypermutator *Pseudomonas aeruginosa* isolates
774 from patients with cystic fibrosis in Australia. *Antimicrobial Agents and Chemotherapy*. **63** (4),
775 e02538-18 (2019).

776 41. Li, Y. et al. Excisionase in Pf filamentous prophage controls lysis-lysogeny decision-
777 making in *Pseudomonas aeruginosa*. *Molecular Microbiology*. **111** (2), 495–513 (2019).

778 42. Van Kampen, A. H. C., Moerland, P. D. Taking bioinformatics to systems medicine.
779 *Systems Medicine*. **1386**, 17–41 (2016).

780 43. Matsushiro, A., Sato, K., Miyamoto, H., Yamamura, T., Honda, T. Induction of
781 prophages of enterohemorrhagic *Escherichia coli* O157:H7 with norfloxacin. *Journal of*
782 *Bacteriology*. **181** (7), 2257–2260 (1999).

783 44. James, C. E. et al. Lytic activity by temperate phages of *Pseudomonas aeruginosa* in
784 long-term cystic fibrosis chronic lung infections. *The ISME Journal*. **9** (6), 1391–1398 (2015).

785 45. Shaw, K. J. et al. Comparison of the changes in global gene expression of *Escherichia*
786 *coli* induced by four bactericidal agents. *Microbial Physiology*. **5** (2), 105–122 (2003).

787 46. Long, H. et al. Antibiotic treatment enhances the genome-wide mutation rate of target
788 cells. *Proceedings of the National Academy of Sciences of the United States of America*. **113**
789 (18), E2498–E2505 (2016).

790 47. González-Tortuero, E. et al. VIGA: A sensitive, precise and automatic de novo Viral
791 Genome Annotator. *bioRxiv*. doi: 10.1101/277509 (2018).